China Rare Disease Drug Catalog: Drug List, Indications, and Approval Information
The China rare disease drug catalog provides an overview of rare disease medicines, including their indications, manufacturers, and approval dates.
Rare diseases affect relatively small patient populations but span diverse conditions, including neurological disorders, blood disorders, inherited metabolic diseases, and rare cancers.
In recent years, China has strengthened its efforts in rare disease drug research, regulatory approvals, and access to innovative treatments, drawing growing global attention to its pharmaceutical market.
The China rare disease drug catalog summarizes relevant medicines, indications, manufacturers, and approval dates, helping global pharmaceutical companies and supply chain stakeholders track developments in China’s rare disease treatment landscape.
The following table summarizes rare disease drug launch information in China for 2026 to date.
👉 For the complete China rare disease drug catalog, please click the link: https://wzogbw.kicp.fun/
| No. | Generic Name | Chinese Generic Name | Indication | Manufacturer | Approval Date |
| 1 | Batoclimab | 巴托利单抗 | Generalized Myasthenia Gravis (gMG) | Harbour BioMed | 2026-10-22 |
| 2 | Pembrolizumab for Subcutaneous Injection | 帕博利珠单抗皮下注射液 | Melanoma | Merck Sharp & Dohme (MSD) | 2026-09-22 |
| 3 | Vosoritide | 伏索利肽 | Achondroplasia | BioMarin Pharmaceutical Inc. | 2026-09-15 |
| 4 | Fibrinogen | 纤维蛋白原 | Coagulation Factor Deficiency | Nanyue Biopharmaceutical Co., Ltd. | 2026-09-15 |
| 5 | Fibrinogen | 纤维蛋白原 | Coagulation Factor Deficiency | Shanghai RAAS Blood Products Co., Ltd. | 2026-09-15 |
| 6 | Somapacitan-beco | 帕西生长素 | Noonan Syndrome | Novo Nordisk | 2026-09-08 |
| 7 | Sotatercept | 索特西普 | Pulmonary Arterial Hypertension (PAH) | Merck Sharp & Dohme (MSD) | 2026-09-08 |
| 8 | Hetrombopag Ethanolamine | 海曲泊帕乙醇胺 | Immune Thrombocytopenia (ITP) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 2026-09-08 |
| 9 | Rilzabrutinib | 利扎布替尼 | Immune Thrombocytopenia (ITP) | Sanofi | 2026-09-03 |
| 10 | Luvometinib Tablets | 芦沃美替尼 | Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibromas (PN) | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | 2026-09-02 |
| 11 | Linvoseltamab Injection | 纬利妥米单抗注射液 | Relapsed or Refractory Multiple Myeloma (RRMM) | Chongqing Genrix Biopharmaceutical Co., Ltd. | 2026-08-25 |
| 12 | Linocopan Fumarate Capsules | 富马酸立康可泮胶囊 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Chengdu Shengdi Pharmaceutical Co., Ltd. | 2026-08-20 |
| 13 | Felzartamab for Injection | 注射用菲泽妥单抗 | Multiple Myeloma (MM) | I-Mab Biopharma (Hangzhou) Co., Ltd. | 2026-08-11 |
| 14 | Recibokibart Injection | 瑞西奇拜单抗 | Generalized Pustular Psoriasis (GPP) | Shanghai Huaota Biopharmaceutical Co., Ltd. | 2026-07-28 |
| 15 | Oveporexton Tablets | 奥普雷顿片 | Narcolepsy Type 1 (NT1) | Takeda | 2026-07-21 |
| 16 | Siptacopan | 思普可泮 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Haisco Pharmaceutical Group Co., Ltd. | 2026-07-21 |
| 17 | Deutetrabenazine | 氘代丁苯那嗪 | Chorea Associated with Huntington’s Disease | Teva Pharmaceuticals | 2026-06-23 |
| 18 | Mepolizumab | 美泊利珠单抗 | Hypereosinophilic Syndrome (HES) | GlaxoSmithKline (GSK) | 2026-06-17 |
| 19 | Apadamtase Alfa | 阿帕达酮α | Thrombotic Thrombocytopenic Purpura (TTP) | Takeda | 2026-06-17 |
| 20 | Lanoracopan Hydrochloride Tablets | 盐酸兰诺可泮片 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Qirui Pharmaceutical Co., Ltd. | 2026-06-10 |
| 21 | Luvometinib Tablets | 芦沃美替尼 | Langerhans Cell Histiocytosis (LCH) | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | 2026-06-10 |
| 22 | Denosumab (CMAB807) | 地舒单抗（CMAB807） | Giant Cell Tumor of Bone (GCTB) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2026-06-09 |
| 23 | Bometase Alfa for Injection | 波米泰酮α | Hemophilia A or B with Inhibitors | Jiangsu Beijietai Biotechnology Co., Ltd. | 2026-06-03 |
| 24 | Nipocalimab | 尼卡利单抗 | Generalized Myasthenia Gravis (gMG) | Johnson & Johnson | 2026-05-19 |
| 25 | Bezacitinib Tablets | 贝泽替普尼 | Myelofibrosis (MF) | Hangzhou Biosun Pharmaceutical Co., Ltd. | 2026-04-29 |
| 26 | Stiripentol | 司替戊醇 | Dravet Syndrome | Biocodex | 2026-04-14 |
| 27 | Benmelstobart Injection | 贝莫苏拜单抗 | Alveolar Soft Part Sarcoma (ASPS) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-14 |
| 28 | Inebilizumab Injection | 伊奈利珠单抗 | Generalized Myasthenia Gravis (gMG) | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 2026-03-27 |
| 29 | Vitamin K1 (Phytonadione) | 维生素K1 | Hypoprothrombinemia and Factor VII Deficiency | CHEPLAPHARM Arzneimittel GmbH | 2026-03-25 |
| 30 | Hetrombopag Ethanolamine | 海曲泊帕乙醇胺 | Aplastic Anemia (AA) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 2026-03-10 |
| 31 | Rovadicitinib | 罗伐替普尼 | Myelofibrosis (MF) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-02-28 |
| 32 | Obinutuzumab Beta Injection | 奥妥珠单抗β | Neuromyelitis Optica Spectrum Disorder (NMOSD) | Beijing Mabworks Biotech Co., Ltd. | 2026-02-10 |
| 33 | Macitentan + Tadalafil | 马昔腾坦 + 他达拉非 | Pulmonary Arterial Hypertension (PAH) | Johnson & Johnson | 2026-01-27 |
| 34 | Fibrinogen | 纤维蛋白原 | Congenital Hypofibrinogenemia or Afibrinogenemia | Tonglu Bioscience Co., Ltd. | 2026-01-27 |
| 35 | Eculizumab | 依库珠单抗 | Generalized Myasthenia Gravis (gMG) | AstraZeneca (Alexion) | 2026-01-16 |
| 36 | Plozasiran Sodium | 普乐司兰钠 | Familial Chylomicronemia Syndrome (FCS) | Arrowhead Pharmaceuticals | 2026-01-05 |
| 37 | Bendamustine | 苯达莫司汀 | Mantle Cell Lymphoma (MCL) | Innopharmax Inc. | 2026-01-02 |
👉 Complete china rare disease catalog: https://wzogbw.kicp.fun/
About DengYueMed
DengYueMed is a Hong Kong-based China pharmaceutical wholesaler specializing in pharmaceutical import and export, procurement, and supply chain services.
The company follows developments in China’s pharmaceutical industry, including rare disease drug approvals and treatment advances, helping global pharmaceutical companies and supply chain stakeholders better understand China’s pharmaceutical market and medicine supply landscape.
Explore Global Pharmaceutical Supply Solutions
FAQ about China Rare Disease Drug Catalog
What Is the China Rare Disease Drug Catalog?
The China rare disease drug catalog provides information on rare disease-related medicines, including drug names, indications, manufacturers, and approval dates.
Where Can I Find Rare Disease Drugs Approved in China?
You can consult NMPA announcements and official drug information to verify rare disease drug approvals in China.
What Information Is Included in the China Rare Disease Drug Catalog?
The catalog may include generic names, Chinese drug names, indications, manufacturers, and approval dates.
How Are Rare Disease Drugs Approved in China?
The National Medical Products Administration (NMPA) evaluates medicines for marketing authorization based on applicable regulatory requirements.
How Can I Access Rare Disease Medicines from China?
DengYueMed is a Hong Kong-based China pharmaceutical wholesaler providing rare disease medicine sourcing, pharmaceutical import and export, procurement, and supply chain services for global partners.
